AbCellera Biologics (ABCL) Assets Average (2021 - 2026)

AbCellera Biologics' Assets Average history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• Quarterly Assets Average fell 1.5% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 1.5% YoY) and the FY2025 annual result came in at $1.4 billion, down 4.6% from the prior year.
• Assets Average was $1.3 billion for Q1 2026 at AbCellera Biologics, down from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.6 billion in Q2 2022 and bottomed at $1.3 billion in Q1 2026.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average soared 39.72% — and 2025, when it declined 8.35%.
• AbCellera Biologics' Assets Average stood at $1.5 billion in 2022, then retreated by 3.01% to $1.5 billion in 2023, then declined by 8.23% to $1.4 billion in 2024, then decreased by 1.47% to $1.4 billion in 2025, then fell by 1.8% to $1.3 billion in 2026.
• Business Quant data shows ABCL's Assets Average at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.